immatics biotechnologies GmbH (4A3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, immatics biotechnologies GmbH (4A3) has a cash flow conversion efficiency ratio of -0.121x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-58.66 Million ≈ $-68.59 Million USD) by net assets (€484.10 Million ≈ $565.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 4A3 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
immatics biotechnologies GmbH - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how immatics biotechnologies GmbH's cash flow conversion efficiency has evolved over time, based on yearly financial data.
immatics biotechnologies GmbH Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of immatics biotechnologies GmbH ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WIZZ AIR HLDG.UNSP.ADR/4
F:WI20
|
N/A |
|
Gemadept Corp
VN:GMD
|
0.025x |
|
Xinxiang Richful Lube Additive Co. Ltd
SHE:300910
|
0.050x |
|
Macmic Science & Technology Co Ltd
SHG:688711
|
0.040x |
|
Sensirion Holding AG
SW:SENS
|
0.098x |
|
Vcanbio Cell & Gene Engineering Corp Ltd
SHG:600645
|
0.028x |
|
Alexanders Inc
NYSE:ALX
|
0.075x |
|
secunet Security Networks Aktiengesellschaft
F:YSN
|
-0.009x |
Annual Cash Flow Conversion Efficiency for immatics biotechnologies GmbH (2019–2025)
The table below shows the annual cash flow conversion efficiency of immatics biotechnologies GmbH from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see immatics biotechnologies GmbH market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €484.10 Million ≈ $565.96 Million |
€-176.63 Million ≈ $-206.49 Million |
-0.365x | -32.72% |
| 2024-12-31 | €574.84 Million ≈ $672.05 Million |
€-158.03 Million ≈ $-184.75 Million |
-0.275x | -439.47% |
| 2023-12-31 | €225.08 Million ≈ $263.15 Million |
€18.23 Million ≈ $21.31 Million |
0.081x | -82.76% |
| 2022-12-31 | €213.16 Million ≈ $249.21 Million |
€100.13 Million ≈ $117.06 Million |
0.470x | -88.71% |
| 2021-12-31 | €24.06 Million ≈ $28.13 Million |
€100.13 Million ≈ $117.06 Million |
4.161x | +333.26% |
| 2020-12-31 | €104.26 Million ≈ $121.89 Million |
€100.13 Million ≈ $117.06 Million |
0.960x | +155.26% |
| 2019-12-31 | €-40.84 Million ≈ $-47.74 Million |
€70.97 Million ≈ $82.97 Million |
-1.738x | -- |
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecific… Read more